These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 11498829)
1. New cytotoxic agents and schedules for advanced breast cancer. Burstein HJ; Bunnell CA; Winer EP Semin Oncol; 2001 Aug; 28(4):344-58. PubMed ID: 11498829 [TBL] [Abstract][Full Text] [Related]
2. Role of gemcitabine in the treatment of advanced and metastatic breast cancer. Heinemann V Oncology; 2003; 64(3):191-206. PubMed ID: 12697958 [TBL] [Abstract][Full Text] [Related]
3. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer. Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068 [TBL] [Abstract][Full Text] [Related]
5. Rationale for the use of gemcitabine in breast cancer (Review). Silvestris N; D'Aprile M; Andreola G; Locopo N; Marini L; Crucitta E; De Lena M; Lorusso V Int J Oncol; 2004 Feb; 24(2):389-98. PubMed ID: 14719116 [TBL] [Abstract][Full Text] [Related]
6. Role of gemcitabine in metastatic breast cancer patients: a short review. Silvestris N; Cinieri S; La Torre I; Pezzella G; Numico G; Orlando L; Lorusso V Breast; 2008 Jun; 17(3):220-6. PubMed ID: 18037292 [TBL] [Abstract][Full Text] [Related]
7. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. Pegram MD; Konecny GE; O'Callaghan C; Beryt M; Pietras R; Slamon DJ J Natl Cancer Inst; 2004 May; 96(10):739-49. PubMed ID: 15150302 [TBL] [Abstract][Full Text] [Related]
8. Rationale for non-platinum chemotherapy in advanced NSCLC. Murren JR Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):29-34. PubMed ID: 11497229 [TBL] [Abstract][Full Text] [Related]
9. Gemcitabine and targeted therapy in metastatic breast cancer. Qu G; Perez EA Semin Oncol; 2002 Jun; 29(3 Suppl 11):44-52. PubMed ID: 12138397 [TBL] [Abstract][Full Text] [Related]
10. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Bunn PA; Kelly K Clin Cancer Res; 1998 May; 4(5):1087-100. PubMed ID: 9607565 [TBL] [Abstract][Full Text] [Related]
11. Optimizing adjuvant chemotherapy in early-stage breast cancer. Perez E; Muss HB Oncology (Williston Park); 2005 Dec; 19(14):1759-67; discussion 1768, 1772-4, 1777-8. PubMed ID: 16506631 [TBL] [Abstract][Full Text] [Related]
12. Trastuzumab/chemotherapy combinations in metastatic breast cancer. Ligibel JA; Winer EP Semin Oncol; 2002 Jun; 29(3 Suppl 11):38-43. PubMed ID: 12138396 [TBL] [Abstract][Full Text] [Related]
13. Present and future treatment of pancreatic cancer. Heinemann V Semin Oncol; 2002 Jun; 29(3 Suppl 9):23-31. PubMed ID: 12094335 [TBL] [Abstract][Full Text] [Related]
14. Weekly docetaxel plus gemcitabine or vinorelbine in refractory advanced breast cancer patients: a parallel dose-finding study. Southern Italy Cooperative Oncology Group (SICOG). Frasci G; Comella P; D'Aiuto G; Thomas R; Capasso I; Elmo M; Botti G; Cortino GR; Lapenta L; De Rosa V; Vallone P; Petrillo A; Comella G Ann Oncol; 2000 Mar; 11(3):367-71. PubMed ID: 10811508 [TBL] [Abstract][Full Text] [Related]
15. Topoisomerase I inhibitors combination chemotherapy in non-small cell lung cancer. Tumolo S; Toffoli G; Saracchini S; Lo Re G; Bruschi G; Boccieri MG Lung Cancer; 2001 Dec; 34 Suppl 4():S37-46. PubMed ID: 11742701 [TBL] [Abstract][Full Text] [Related]
17. Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review. Clegg A; Scott DA; Hewitson P; Sidhu M; Waugh N Thorax; 2002 Jan; 57(1):20-8. PubMed ID: 11809985 [TBL] [Abstract][Full Text] [Related]
18. State-of-the-art chemotherapy for advanced breast cancer. Piccart MJ; Awada A Semin Oncol; 2000 Oct; 27(5 Suppl 9):3-12. PubMed ID: 11049051 [TBL] [Abstract][Full Text] [Related]
19. Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline-pretreated metastatic breast cancer. Verma S; Ilersich AL Oncologist; 2003; 8(3):232-40. PubMed ID: 12773745 [TBL] [Abstract][Full Text] [Related]
20. Evaluating new treatments for advanced cancer. Botwood N Br J Cancer; 2001 Jul; 85(1):139-40. PubMed ID: 11437417 [No Abstract] [Full Text] [Related] [Next] [New Search]